Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul 1;20(13):e786-e788.
doi: 10.4244/EIJ-E-24-00035.

Angioplasty with drug-coated balloon catheters: the coming tide?

Robert A Byrne  1   2 , Rory Durand  1   2
Affiliations
Editorial

Angioplasty with drug-coated balloon catheters: the coming tide?

Robert A Byrne et al. EuroIntervention. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

R.A. Byrne reports research grants received by the institutions of employment from Abbott, Biosensors, Boston Scientific, and Translumina, without impact on personal remuneration; he does not accept personal payments from the medical device or pharmaceutical industry. R. Durand has no conflicts of interest to declare in relation to this work.

Figures

Figure 1
Figure 1. Comparative rates of percentage diameter stenosis at angiographic follow-up in randomised trials of biolimus A9-coated balloons versus control.
Xu et al reported superior efficacy of a biolimus A9-coated balloon compared to plain balloon angioplasty in patients with small vessel coronary artery disease in the BIO-RISE CHINA study. The REFORM trial failed to show non-inferiority of a biolimus A9-coated balloon compared to a paclitaxel-coated balloon for percentage diameter stenosis at 6 months. The current BIO ASCEND ISR trial shows similar efficacy of a biolimus A9-coated balloon to a paclitaxel-coated balloon. DCB: drug-coated balloon
See this image and copyright information in PMC

References

    1. Byrne RA, Durand R. Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease: One Step Forward, Two Steps Back. JACC Cardiovasc Interv. 2023;16:2897–9. - PubMed
    1. Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention. 2022;18:e103–23. - PMC - PubMed
    1. Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, Pérez-Vizcayno MJ, Kang DY, Degenhardt R, Pleva L, Baan J, Cuesta J, Park DW, Schunkert H, Colleran R, Kukla P, Jiménez-Quevedo P, Unverdorben M, Gao R, Naber CK, Park SJ, Henriques JPS, Kastrati A, Byrne RA. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J. 2020;41:3715–28. - PMC - PubMed
    1. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. 2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention. 2019;14:1435–534. - PubMed
    1. Authors/Task Force Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources